Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation
https://www.zacks.com/stock/news/2216453/key-takeaways-from-jnj-s-jnj-q4-earnings-presentation?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2216453
Jan 26, 2024 - J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.
0
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
https://www.zacks.com/stock/news/2217364/will-amgen-amgn-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2217364
Jan 29, 2024 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-2220511
Feb 02, 2024 - AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
0
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529
Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
0
PBYI vs. AMGN: Which Stock Should Value Investors Buy Now?
https://www.zacks.com/stock/news/2224255/pbyi-vs-amgn-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2224255
Feb 09, 2024 - PBYI vs. AMGN: Which Stock Is the Better Value Option?
0
Where Are Biotech ETFs Headed After Q4 Earnings?
https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390
Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
0
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
https://www.zacks.com/stock/news/2244204/acelyrin-slrn-up-on-data-from-thyroid-eye-disease-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244204
Mar 21, 2024 - ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.
0
Wall Street Awaits Consumer Confidence Data
https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data?cid=CS-ZC-FT-economic_highlights-2246106
Mar 26, 2024 - Wall Street Awaits Consumer Confidence Data
0
Is Amgen a Good Dividend Stock to Buy Right Now?
https://www.fool.com/investing/2024/01/29/is-amgen-a-good-dividend-stock-to-buy-right-now/?source=iedfolrf0000001
Jan 29, 2024 - Its diverse product mix and strong fundamentals make a decent case.
0
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
https://www.zacks.com/stock/news/2218010/amgen-amgn-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2218010
Jan 30, 2024 - Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Pages: 12
Page 1